Abeona Therapeutics Inc.
ABEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.04 | 0.01 | 0.07 |
| FCF Yield | -25.57% | -34.86% | -180.11% | -208.57% |
| EV / EBITDA | -4.03 | -1.94 | -0.51 | -0.13 |
| Quality | ||||
| ROIC | -64.80% | -91.39% | -63.65% | -138.68% |
| Gross Margin | 0.00% | 54.14% | 68.18% | -48.80% |
| Cash Conversion Ratio | 0.88 | 0.68 | 1.10 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 5.27% | -47.90% | – |
| Free Cash Flow Growth | -56.56% | 14.38% | 37.53% | -92.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.18 | 0.19 | 0.31 |
| Interest Coverage | -15.26 | -112.76 | -61.49 | -24.48 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -432.05 | -167.66 | -1,420.39 | 324.24 |